Table 1 |
|||||||
|
Smoking,alcohol drinkingand antibody response following pneumococcal vaccination in entire study population/different groups |
|||||||
|
All participants |
(I) RA on MTX |
(II) RA on anti-TNF as monotheraphy |
(III) RA on anti-TNF+ MTX |
(IV) SpA on anti-TNF as monotherapy |
(V) SpA on anti-TNF+MTX |
(VI) SpA on NSAID/analgesics |
|
|
|
|||||||
|
Number of patients at vaccination |
505 |
85 |
79 |
89 |
83 |
83 |
86 |
|
|
|||||||
|
Females (%) |
63 |
79 |
87 |
78 |
34 |
53 |
45 |
|
|
|||||||
|
CRP g/L (mean) |
6.7 |
8.9 |
9.4 |
5.9 |
2.9 |
5.1 |
7.7 |
|
|
|||||||
|
ESR mm/h (mean) |
21.5 |
28.3 |
28.6 |
24.4 |
11.7 |
15.3 ( 5 15.3 |
19.8 |
|
|
|||||||
|
Current smokers (%) |
17 |
19 |
19 |
18 |
12 |
24 |
12 |
|
|
|||||||
|
Ex-smokers (%) |
40 |
39 |
38 |
45 |
45 |
39 |
35 |
|
|
|||||||
|
Ever-smokers (%) |
57.4 |
56.5 |
57.0 |
65.2 |
55.4 |
60.2 |
44.2 |
|
|
|||||||
|
Smoking pack-years; mean (SD) |
19.4 (14) |
22.0 (13) |
21.0 (15) |
20.4 (14) |
16.0 (13) |
19.4 (13) |
16.8 (13) |
|
|
|||||||
|
Current alcohol drinking (g/week) mean (SD) |
9.7 (9) |
13.2 (11) |
8.0 (9) |
10.4 (13) |
12.2 (12) |
8.5 (8) |
11.8 (9) |
|
|
|||||||
|
IgG at vaccination (g/L)(SD) |
10.4 (2.7) |
9.7 (2.5) |
11.8 (3.3) |
11.0 (3.3) |
9.9 (1.9) |
9.9 (2.2) |
9.9 (2.1) |
|
|
|||||||
|
IgM at vaccination (g/L)(SD) |
1.3 (0.8) |
1.1 (0.6) |
1.7 (1.0) |
1.4 (0.7) |
1.3 (0.8) |
1.2 (0.7) |
1.0 (0.6) |
|
|
|||||||
|
IgA at vaccination (g/L)(SD) |
2.7 (1.2) |
2.5 (1.0) |
3.3 (1.4) |
2.8 (1.2) |
2.7 (1.1) |
2.4 (1.1) |
2.5 (1.1) |
|
|
|||||||
|
Immune response (IR) for 23F (mean) 1 |
3.5 |
2.5 |
3.4 |
2.2 |
4.8 |
3.0 |
6.6 |
|
|
|||||||
|
Immune response (IR) 1 for 6B (mean) |
2.3 |
1.8 |
2.7 |
1.6 |
3.1 |
1.8 |
3.3 |
|
|
|||||||
|
Patients with protective antibody levels for both 23F and 6B 4-6 weeks after vaccination (%)(posIR) 2 |
32.9 |
21.2 |
36.7 |
15.7 |
50.6 |
20.5 |
47.7 |
|
|
|||||||
|
1Immune response = ratio between post- and prevaccination antibody levels. 2 Positive immune response (posIR) was defined as IR ≥2. |
|||||||
|
Roseman et al. Arthritis Research & Therapy 2012 14:R170 doi:10.1186/ar3923 |
|||||||